Advertiment
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA’s initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN). Under the terms of the agreement, Idera is entitled to receive a payment of 3.0 million euros (approximately 3.8 million dollars) from Merck KGaA.
“We are very pleased that Merck KGaA has initiated a clinical trial to evaluate IMO-2055 in the first-line treatment of patients with head and neck cancer,” said Tim Sullivan, Ph.D., Idera’s Vice President of Development Programs and Alliance Management. “The first-line trial is in addition to the Phase 2 clinical trial announced earlier this year to evaluate IMO-2055 in second-line treatment of patients with recurrent or metastatic SCCHN.”
About the Collaboration
Idera Pharmaceuticals entered into a worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany in December 2007 for the research, development and commercialization of Idera’s Toll-like Receptor 9 (TLR9) agonists, including IMO-2055, for the potential treatment of cancers. In addition to the clinical study announced today, under the company’s collaboration with Merck KGaA, IMO-2055 is being evaluated in a Phase 2 clinical trial in combination with Erbitux® in second-line patients with recurrent or metastatic SCCHN, in a Phase 1b clinical trial in combination with erlotinib (Tarceva®) and bevacizumab (Avastin®) in patients with advanced non-small cell lung cancer and in a Phase 1b clinical trial in combination with Erbitux® and an irinotecan-containing treatment regimen in patients with colorectal cancer.
Source:
Idera Pharmaceuticals, Inc.
Leave a Reply
Suggested Posts
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC Idera Pharmaceuticals, I c. (Nasdaq: IDRA), a ou ced that it has achieved a milesto e u der its worldwide lice si g a d collaboratio agreeme t with Merck KGaA, Darmstadt, Germa y. The milesto e was achieved upo Merck KGaA’s i itiatio of a Phase 1b cli ical trial of IMO-2055 (EMD 1201081), a ago ist of Toll-like Receptor 9 (TLR9), i combi atio with cisplati , fluorouracil a d [...]. Posted August 30th, 2010 | 11:40 am
New Evidence Strengthens Link Between Opioids And Cancer Growth Idera Pharmaceuticals, I c. (Nasdaq: IDRA), a ou ced that it has achieved a milesto e u der its worldwide lice si g a d collaboratio agreeme t with Merck KGaA, Darmstadt, Germa y. The milesto e was achieved upo Merck KGaA’s i itiatio of a Phase 1b cli ical trial of IMO-2055 (EMD 1201081), a ago ist of Toll-like Receptor 9 (TLR9), i combi atio with cisplati , fluorouracil a d [...]. Posted August 30th, 2010 | 11:40 am
Two Cancer-Promoting Pathways Linked In Esophageal Cancer Idera Pharmaceuticals, I c. (Nasdaq: IDRA), a ou ced that it has achieved a milesto e u der its worldwide lice si g a d collaboratio agreeme t with Merck KGaA, Darmstadt, Germa y. The milesto e was achieved upo Merck KGaA’s i itiatio of a Phase 1b cli ical trial of IMO-2055 (EMD 1201081), a ago ist of Toll-like Receptor 9 (TLR9), i combi atio with cisplati , fluorouracil a d [...]. Posted August 30th, 2010 | 11:40 am
Using Molecular Analysis To Identify Specific Cancers Idera Pharmaceuticals, I c. (Nasdaq: IDRA), a ou ced that it has achieved a milesto e u der its worldwide lice si g a d collaboratio agreeme t with Merck KGaA, Darmstadt, Germa y. The milesto e was achieved upo Merck KGaA’s i itiatio of a Phase 1b cli ical trial of IMO-2055 (EMD 1201081), a ago ist of Toll-like Receptor 9 (TLR9), i combi atio with cisplati , fluorouracil a d [...]. Posted August 30th, 2010 | 11:40 am
Establishing National Standards For Cancer Survivorship Care Idera Pharmaceuticals, I c. (Nasdaq: IDRA), a ou ced that it has achieved a milesto e u der its worldwide lice si g a d collaboratio agreeme t with Merck KGaA, Darmstadt, Germa y. The milesto e was achieved upo Merck KGaA’s i itiatio of a Phase 1b cli ical trial of IMO-2055 (EMD 1201081), a ago ist of Toll-like Receptor 9 (TLR9), i combi atio with cisplati , fluorouracil a d [...]. Posted August 30th, 2010 | 11:40 am